Back to Journals » Lung Cancer: Targets and Therapy

ESCI
SJR OA
CiteScore
Impact Factor

Lung Cancer: Targets and Therapy

ISSN: 1179-2728


       

Editor-in-Chief: Professor Sai-Hong Ignatius Ou

An international, peer-reviewed, open access journal focusing on lung cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).

Articles:

Latest articles:

- 5 records -

Original Research

Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer

Shi J, Li J, Wang H, Li X, Wang Q, Zhao C, Cheng L, Han R, Chen P, Guo H, Tang Z, Zhou C, Zhang Z, Wu F

Lung Cancer: Targets and Therapy 2023, 14:85-99

Published Date: 21 November 2023

Case report

Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib

Wang L, Quan F, Guo Z, Lu Z, Yang D, Shi M

Lung Cancer: Targets and Therapy 2023, 14:79-84

Published Date: 9 October 2023

Perspectives

ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia

Lee AT, Ou SI

Lung Cancer: Targets and Therapy 2023, 14:71-78

Published Date: 7 July 2023

Commentary

The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?

Brazel D, Ou SI

Lung Cancer: Targets and Therapy 2023, 14:63-69

Published Date: 23 June 2023

Commentary

From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting

Lee AT, Ou SI

Lung Cancer: Targets and Therapy 2023, 14:57-62

Published Date: 22 June 2023


Read more articles